News

Early treatment with the investigational small molecule golexanolone improved motor and cognitive function and eased signs of fatigue, anxiety, and depression in a rat model of Parkinson’s disease. The Umecrine Cognition treatment also reduced neuroinflammation and improved dopamine levels, a study found. Golexanolone “could be considered for clinical evaluation…

The Michael J. Fox Foundation (MJFF) has awarded a $2 million grant to Enigma Biomedical USA for the development and first preclinical testing of a new positron emission tomography (PET) tracer that targets harmful clumps of the protein alpha-synuclein, a hallmark and suspected driver of Parkinson’s disease. The…

Vincere Biosciences won a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance development of USP30 small molecule inhibitors, its candidate therapy aimed at slowing or halting Parkinson’s disease progression. The grant, provided through MJFF’s Therapeutics Pipeline Program, will…

The American Parkinson Disease Association (APDA) has announced three recipients of its inaugural Bridge Funding Awards, a program designed to support promising Parkinson’s disease research when unexpected gaps in funding occur. The awards were open specifically to researchers APDA has funded within the…

Researchers creating a map of the developing human brain found that methods used to grow brain cells lost in Parkinson’s disease often inadvertently create other types as well, pointing to the need for more refined modeling. The scientists developed a framework that “provides a foundation for refining protocols toward…

Texas voters a a $3 billion state investment to support research into brain diseases such as Parkinson’s disease, a measure the Michael J. Fox Foundation for Parkinson’s Research (MJFF) called “a decisive step toward transforming the future of brain health and establishing itself as a model for other…

In people with early Parkinson’s disease, buntanetap slowed cognitive decline, with the biggest gains seen in those with mild dementia. Researchers also noted that about a quarter of these patients showed signs of amyloid buildup — a marker linked to Alzheimer’s disease — and…

Annovis Bio has scheduled a January meeting with the U.S. Food and Drug Administration (FDA) to discuss buntanetap as a treatment for dementia due to Parkinson’s disease. The meeting will include discussions about potential clinical trial design, the criteria that will be used to determine which patients…

Researchers have uncovered a previously overlooked type of electrical brain activity — an irregular signal they call noise — that closely tracks the severity of motor symptoms in people with Parkinson’s disease. The discovery, made by scientists at the Max Planck Institute in Germany, in collaboration with research teams…

A $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will help Booster Therapeutics develop therapeutics to improve the body’s ability to clear disease-causing proteins that drive Parkinson’s disease. The research grant will support studies into small-molecule therapeutics that activate the proteasome, a cellular…